| Literature DB >> 31878048 |
Van Bon Nguyen1,2, Shan-Ping Chen3, Thi Hanh Nguyen4, Minh Trung Nguyen5, Thi Thanh Thao Tran5, Chien Thang Doan5, Thi Ngoc Tran5, Anh Dzung Nguyen4, Yao-Haur Kuo6, San-Lang Wang3,7.
Abstract
Marine chitins (Entities:
Keywords: Serratia marcescens; anti-tumors; bioprocessing; prodigiosin; α-Chitin
Mesh:
Substances:
Year: 2019 PMID: 31878048 PMCID: PMC7024390 DOI: 10.3390/md18010015
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1The effect of chitin/protein ratio. The chitin including two forms of α-chitin and β-chitin were mixed with free protein (casein) with six ratios of 1/7, 2/6, 4/4, 5/3, 6/2, and 7/1 (w/w) and used as the sole carbon and nitrogen source with the concentration of 1.5% (w/v). The fermentation was performed at the conditions at 30 °C in 1 d, and then at 25 °C in next 2 d, shaking speed of 150 rpm, and a ratio volume of medium: flask of 1:2.5 (v/v).
Comparison of the prodigiosin yield (mg/100mL) produced by different Serratia marcescens strains.
| PG – Producing Strains | C/N Source | |
|---|---|---|
| 0.94% α-Chitin + 0.56% Casein | 1.5% Squid Pens | |
| 335 ± 14.4 a | 243 ± 24.8 b | |
| 227 ± 2.93 b | 150 ± 5.77 c | |
| 329 ± 16.7 a | 240 ± 17.3 b | |
| 325 ± 14.4 a | 236 ± 20.8 b | |
| No bacteria | - | - |
Means of prodigiosin yield (mg/100mL) values with the same letter are not significantly different based on Duncan’s multiple range test (alpha = 0.01). CV% = 4.271394. (-): no prodigiosin was detected.
Comparison of the prodigiosin yield produced by S. marcescens in different reports.
| PG – Producing Strains | C/N Source | Prodigiosin (mg/100mL) | Reference |
|---|---|---|---|
| 0.94% α-chitin + 0.56% Casein | 335 | This study | |
| 1.5% squid pens | 97.8 | [ | |
| 1.5% peanut powder | 116.8 | [ | |
| 1.0% shrimp shells powders | 19 | [ | |
| 1.0% crab shells powders | 11 | [ | |
| 1.0% shrimp heads powders | 3 | [ | |
| 1.5% squid pens | 248 | [ | |
|
| 2.0% peanut seed | 387.5 | [ |
|
| 2.0% peanut oil | 289 | [ |
|
| 2.0% sesame seed | 1668 | [ |
|
| 2.0% sesame oil | 100.6 | [ |
|
| 2.0% copra seed | 194 | [ |
|
| 2.0% coconut oil | 142 | [ |
| Modified Luria-Bertani broth, 6.0% sunflower oil | 79 | [ | |
| 5 g/L yeast extract as sole N/C source | 69 | [ | |
| 2% tryptone/glycerol (1/1) | 12.5 | [ | |
| 100 mM 3-[ | 47.5 | [ | |
| 6.97 g/L of peanut powder, 11.29 mL/L of olive oil and 16.02 g/L of beef extract | 1362.2 | [ | |
| 1% Soya peptone | 117.4 | [ | |
| 1% Tryptone | 35.3 | [ | |
| 1% Yeast extract | 38.02 | [ | |
| 1% Fish meal | 0 | [ | |
| 1% Soybean powder | 0 | [ | |
| 1% Corn steep liquor | 0 | [ |
Figure 2The effect of carbohydrate (a) and protein (b) sources on the prodigiosin production by S. marcescens TKU11. Carbohydrate and protein were mixed at the ratio of 5/3 and used as the C/N source. The culture medium contains 1.5% C/N source, 0.1% K2HPO4 and 0.1% FeSO4(NH4)2SO4. The fermentation was performed at the conditions at 30 °C in 1 d, and then at 25 °C over the next 2 d, shaking speed of 150 rpm, and a ratio volume of medium:flask of 1:2.5 (v/v). Means of prodigiosin yield (mg/100mL) values with the same letter in each figure are not significantly different based on Duncan’s multiple range test (alpha = 0.01).
Figure 3The effect of phosphate salts (a,b), sulfate salts (c,d), cultivation temperature (e), pH of culture medium (f), and cultivation time (g) on the prodigiosin production by S. marcescens TKU011. Medium with the combination of α-chitin and casein with the ratio of 5/3 (w/w). The culture medium containing 1.5% C/N source, 0.1% FeSO4(NH4)2SO4 (a,b), 0.05% K2HPO4 (c,d). The fermentation was performed at 30 °C in 1 d, and then at 25 °C in the next 2 d, shaking speed of 150 rpm, and a ratio volume of medium: flask of 1:2.5 (v/v). Means of prodigiosin yield (mg/100mL) values with the same letter in each figure are not significantly different based on Duncan’s multiple range test (alpha = 0.01).
Figure 4The purification and isolation process of prodigiosin. The culture broth containing prodigiosin (a) was extract by ethyl acetate (b). The crude prodigiosin was further separated by silica gel column (c) and then isolated by thin layer chromatography (TLC) (d).
Figure 5UV spectrum of purified prodigiosin newly biosynthesized from the novel designed substrate (α-chitin/casein = 5/3) by S. marcescens TKU011.
Figure 6MALDI-TOF MS (Matrix-Assisted Laser Desorption Ionization - Time of Flight Mass Spectrometry) spectra of purified prodigiosin. 2,5-dihydroxybenzoic acid was used as a matrix in CAN-TFA-H2O solution (50/0.1/50%, v/v/v) to separate the sample in the MALDI-TOF instrument (Bruker Daltonics, Bremen, Germany) with a nitrogen laser emitting at 337 nm, operating in linear mode. Each spectrum of mass was calculated based on the data of around 30–50 laser shots, and external calibration with three points was used for assignment of mass [36].
Max inhibition against cancerous cell lines of prodigiosin.
| Max Inhibition Against Cancerous Cell Lines (%) | ||||
|---|---|---|---|---|
| MCF-7 | A549 | Hep G2 | WiDr | |
| Crude sample | 91.6 ± 1.76 a,b | 89.2 ± 1.43 b | 93.2 ± 2.12 a,b | 79.4 ± 1.72 c |
| Purified Prodigiosin | 92.5 ± 1.4 a,b | 92.6 ± 1.9 a,b | 93.9 ± 2.0 a | 90.2 ± 1.12 a,b |
| Mitomycin C | 94.1 ± 1.61a | 93.3 ± 1.54 a,b | 91.7 ± 1.01 a,b | 92.6 ± 1.02 a,b |
The samples were tested at their concentration of 10 µg/mL for their anticancer activity against MCF-7 (Human breast adenocarcinoma), A549 (Human lung carcinoma), Hep G2 (Human hepatocellular carcinoma), and WiDr (Human colon adenocarcinoma). The means of inhibition (%) with the same letter are not significantly different based on Duncan’s multiple range test (alpha = 0.01). CV (%) = 1.979533.
Anticancer activities of prodigiosin.
| Inhibition Against Cancerous Cell Lines (IC50, µg/mL) | ||||
|---|---|---|---|---|
| MCF-7 | A549 | Hep G2 | WiDr | |
| Crude sample | 0.44 ± 0.09 c,b | 0.46 ± 0.01 b | 0.38 ± 0.01 c,b | 0.88 ± 0.05 a |
| Purified Prodigiosin | 0.04 ± 0.01 e | 0.06 ± 0.01 e | 0.04 ± 0.01 e | 0.20 ± 0.03 d |
| Mitomycin C | 0.11 ± 0.01 e | 0.10 ± 0.01 e | 0.13 ± 0.01 e | 0.10 ± 0.01 e |
The samples were tested at their concentration range of 0.01–10 µg/mL for their anticancer activity against MCF-7 (Human breast adenocarcinoma), A549 (Human lung carcinoma), Hep G2 (Human hepatocellular carcinoma), and WiDr (Human colon adenocarcinoma). Means of IC50 (µg/mL) values with the same letter are not significantly different based on Duncan’s multiple range test (alpha = 0.01). CV% = 12.9069.